Clinical characteristics of 19 HIV-positive mothers and their infants
| Patient No. . | CD4 count, cells/μL . | HIV RNA, copies/mL . | Antiretroviral treatment, Antepartum (from week) . | Antiretroviral treatment, intrapartum . | Antiretroviral treatment, postpartum . | GA, wk . | Mode of delivery . |
|---|---|---|---|---|---|---|---|
| 1 | 445 | ND | AZT (14) | AZT | AZT | 38 | Cesarean section |
| 2, 3 | 187 | ND | AZT (17) | AZT | AZT | 34 | Cesarean section |
| 4 | 858 | ND | AZT (20) | AZT | AZT | 38 | Cesarean section |
| 5 | 379 | ND | AZT (14) | AZT | AZT | 37 | Cesarean section |
| 6 | 227 | 14 000 | AZT, ddI (18) | AZT | AZT | 31 | Cesarean section |
| 7 | 221 | 34 000 | AZT, 3TC (16) | AZT | AZT | 37 | Cesarean section |
| 8 | 209 | < 100 | AZT (27) | AZT | AZT | 41 | Vaginal |
| 9 | 478 | 28 | AZT (20) | AZT | AZT | 38 | Cesarean section |
| 10 | 598 | 1 886 | AZT, 3TC (14) | AZT | AZT | 38 | Cesarean section |
| 11 | 165 | 291 | AZT, 3TC, IND (0) | AZT | AZT | 38 | Cesarean section |
| 12 | 80 | 1 301 | AZT, 3TC, IND (32) | AZT | AZT | 38 | Cesarean section |
| 13 | 385 | 119 | AZT (14) | AZT | AZT | 38 | Cesarean section |
| 14 | 348 | < 20 | D4T, 3TC, NEV (0) | AZT | AZT | 38 | Cesarean section |
| 15 | 330 | < 20 | AZT, 3TC, NEV (24) | AZT | AZT | 38 | Cesarean section |
| 16 | 299 | < 20 | AZT, 3TC, ddI, NEV (14) | AZT | AZT | 38 | Cesarean section |
| 17 | 352 | 1 173 | None | None | None | 40 | Vaginal |
| 18 | 336 | < 20 | AZT, 3TC, NFV (16) | AZT | AZT | 38 | Cesarean section |
| 19 | 621 | < 200 | AZT, 3TC (30) | AZT | AZT | 38 | Cesarean section |
| 20 | 430 | < 20 | AZT, 3TC, NEV (24) | AZT | AZT | 38 | Cesarean section |
| Patient No. . | CD4 count, cells/μL . | HIV RNA, copies/mL . | Antiretroviral treatment, Antepartum (from week) . | Antiretroviral treatment, intrapartum . | Antiretroviral treatment, postpartum . | GA, wk . | Mode of delivery . |
|---|---|---|---|---|---|---|---|
| 1 | 445 | ND | AZT (14) | AZT | AZT | 38 | Cesarean section |
| 2, 3 | 187 | ND | AZT (17) | AZT | AZT | 34 | Cesarean section |
| 4 | 858 | ND | AZT (20) | AZT | AZT | 38 | Cesarean section |
| 5 | 379 | ND | AZT (14) | AZT | AZT | 37 | Cesarean section |
| 6 | 227 | 14 000 | AZT, ddI (18) | AZT | AZT | 31 | Cesarean section |
| 7 | 221 | 34 000 | AZT, 3TC (16) | AZT | AZT | 37 | Cesarean section |
| 8 | 209 | < 100 | AZT (27) | AZT | AZT | 41 | Vaginal |
| 9 | 478 | 28 | AZT (20) | AZT | AZT | 38 | Cesarean section |
| 10 | 598 | 1 886 | AZT, 3TC (14) | AZT | AZT | 38 | Cesarean section |
| 11 | 165 | 291 | AZT, 3TC, IND (0) | AZT | AZT | 38 | Cesarean section |
| 12 | 80 | 1 301 | AZT, 3TC, IND (32) | AZT | AZT | 38 | Cesarean section |
| 13 | 385 | 119 | AZT (14) | AZT | AZT | 38 | Cesarean section |
| 14 | 348 | < 20 | D4T, 3TC, NEV (0) | AZT | AZT | 38 | Cesarean section |
| 15 | 330 | < 20 | AZT, 3TC, NEV (24) | AZT | AZT | 38 | Cesarean section |
| 16 | 299 | < 20 | AZT, 3TC, ddI, NEV (14) | AZT | AZT | 38 | Cesarean section |
| 17 | 352 | 1 173 | None | None | None | 40 | Vaginal |
| 18 | 336 | < 20 | AZT, 3TC, NFV (16) | AZT | AZT | 38 | Cesarean section |
| 19 | 621 | < 200 | AZT, 3TC (30) | AZT | AZT | 38 | Cesarean section |
| 20 | 430 | < 20 | AZT, 3TC, NEV (24) | AZT | AZT | 38 | Cesarean section |
3TC indicates lamivudine; ddI, dideoxynosine; D4T, stavudine; IND, indinavir; NEV, nevirapine; NFV, nelfinavir; GA, gestational age; and AZT, antiviral therapy including zidovudine.